Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Gastric cancer (GC) is a malignancy with a high incidence and mortality, and the emergence
of immunotherapy has brought survival benefits to GC patients. Compared with traditional …

BACKGROUND Gastric cancer (GC) is the sixth most common cancer and third leading
cause of cancer-related deaths worldwide. Current treatments mainly rely on surgery-and …

Gastric cancer (GC) is one of the most common malignancies. Immunotherapy becomes an
indispensable part of GC. This study conducts bibliometric analysis of immunotherapy for …

Gastric cancer (GC) is one of the most common gastrointestinal tract cancers worldwide,
which has high incidence and mortality rates and poor prognosis. Although multidisciplinary …

The tumor microenvironment, particularly the immune microenvironment, plays an
indispensable role in the malignant progression and metastasis of gastric cancer (GC). As …

In this editorial, we comment on the article entitled “Advances and key focus areas in gastric
cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999 …

The results of genomic and molecular profiling of cancer patients can be effectively applied
to immunotherapy agents, including immune checkpoint inhibitors, to select the most …

Gastric cancer, a prevalent malignancy worldwide, ranks sixth in terms of frequency and
third in fatality, causing over a million new cases and 769000 annual deaths. Predominant in …

Colorectal cancer (CRC) is the second most cancer-related death worldwide. In recent
years, probiotics have been used to reduce the potential risks of CRC and tumors with …